Johnson & Johnson (NYSE:JNJ) was upgraded by stock analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating in a research note issued on Wednesday. The brokerage presently has a $157.00 target price on the stock, up from their previous target price of $145.00. Jefferies Group LLC’s price objective suggests a potential upside of 14.74% from the company’s current price. Jefferies Group also issued estimates for Johnson & Johnson’s FY2017 earnings at $7.22 EPS, FY2018 earnings at $8.18 EPS, FY2019 earnings at $8.96 EPS, FY2020 earnings at $9.69 EPS and FY2021 earnings at $10.58 EPS.
A number of other equities analysts have also recently issued reports on JNJ. Cowen and Company set a $147.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, October 6th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $120.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 4th. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. J P Morgan Chase & Co raised their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research note on Wednesday, August 16th. Finally, Citigroup Inc. assumed coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 price objective on the stock. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $135.98.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the prior year, the firm earned $1.74 earnings per share. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year.
TRADEMARK VIOLATION WARNING: “Jefferies Group LLC Upgrades Johnson & Johnson (JNJ) to Buy” was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thestockobserver.com/2017/10/13/jefferies-group-llc-upgrades-johnson-johnson-jnj-to-buy.html.
In related news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of JNJ. Capital Asset Advisory Services LLC acquired a new position in Johnson & Johnson during the first quarter worth $219,000. First National Bank of Omaha raised its holdings in Johnson & Johnson by 8.0% during the first quarter. First National Bank of Omaha now owns 52,648 shares of the company’s stock worth $6,558,000 after buying an additional 3,919 shares during the last quarter. Stillwater Capital Advisors LLC raised its holdings in Johnson & Johnson by 46.2% during the first quarter. Stillwater Capital Advisors LLC now owns 87,867 shares of the company’s stock worth $10,944,000 after buying an additional 27,785 shares during the last quarter. TNB Financial acquired a new position in Johnson & Johnson during the first quarter worth $3,438,000. Finally, Horan Capital Management raised its holdings in Johnson & Johnson by 5.8% during the first quarter. Horan Capital Management now owns 66,552 shares of the company’s stock worth $8,289,000 after buying an additional 3,633 shares during the last quarter. 65.90% of the stock is currently owned by institutional investors and hedge funds.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.